A Phase 3 interventional study of Letermovir tablet and Letermovir IV in Cytomegalovirus Infection and Cytomegalovirus Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 13th largest by enrollment, is one of 4 that started in 2019, is one of 6 in phase 3, and was the 4th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
Elisabeth Kincaide · Sites in United States
Ages 18+
Hospital do Rim e Hipertensão
Ages 18+
By country, each count listing its studies:
letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2019.
This study's enrollment of 22 is below the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies testing letermovir in Cytomegalovirus Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407232Phase 3University of Wisconsin, MadisonLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | 2027-08 |
| NCT06334497Phase 3Assistance Publique - Hôpitaux de ParisLetermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections | 2027-09 |
| NCT06066957University of PennsylvaniaOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | 2026-12-15 |
| NCT06057194Maimónides Biomedical Research Institute of CórdobaEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
Drug: Letermovir tablet · Drug: Letermovir IV
A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
Also known as: MK-8228, PREVYMIS®
IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
Also known as: MK-8228, PREVYMIS®
Percentage of Participants With Adverse Events (AEs)
Percentage of participants with one or more adverse events (AEs)
Time frame: Up to week 52 post-transplant
Percentage of Participants Who Discontinued From Study Drug Due to an AE
Percentage of participants who discontinued from study drug due to an AE
Time frame: Up to week 28 post-transplant
Percentage of Participants With Adjudicated CMV Disease or Undergone Anti-CMV Treatment
CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Participants who have undergone anti-CMV treatment was defined as initiation of approved anti-CMV agents based on at least one positive cell on CMV antigenemia and/or quantifiable CMV DNA PCR assay performed locally.
Time frame: Up to Week 52 post-transplant
Percentage of Participants With Adjudicated CMV Disease
CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included.
Time frame: Up to Week 52 post-transplant
Percentage of Participants With Quantifiable CMV DNAemia
Quantifiable CMV DNAemia (central) was defined as any case with a numeric value or \>910,000,000 (not including reporting of PCR results as "detected, not quantifiable") using the Roche COBAS® AmpliPrep/COBAS TaqMan® (CAP/CTM) assay, which was performed by the central laboratory.
Time frame: Up to Week 52 post-transplant
Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment
AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an oral administration of letermovir.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment
Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an oral administration of letermovir.
Time frame: Any day between Days 6-10: 24hrs post-dose
Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment
Cmax was defined as the maximum concentration of letermovir observed in plasma following an oral administration of letermovir.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment
Tmax was defined as the time required post dosing to reach a maximum plasma concentration of letermovir following an oral administration of letermovir.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment
Apparent clearance at steady state (CLss/F) of plasma letermovir following an oral administration of letermovir.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir - IV Treatment
AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an IV administration of letermovir was intended to measure.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Trough Concentration (Ctrough) of Plasma Letermovir - IV Treatment
Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an IV administration of letermovir was intended to measure.
Time frame: Pre-dose on Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 and 28
Concentration at the End of Infusion (Ceoi) of Plasma Letermovir - IV Treatment
Ceoi is defined as the amount of letermovir in plasma following an IV administration of letermovir was intended to measure.
Time frame: Any day between Days 6-10: at end of infusion (1 hours post dose)
Clearance at Steady State (CLss) of Plasma Letermovir - IV Treatment
Clearance at steady state (CLss) of plasma letermovir following an IV administration of letermovir was intended to measure.
Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
This study enrolled adult Japanese kidney transplant recipients who are organ donor (D) or organ recipient (R) seropositive (D+/R-, D+/R+ or D-/R+) for Cytomegalovirus (CMV) as participants.
| Milestone | Letermovir |
|---|---|
| Started | 22 |
| Completed | 20 |
| Not completed | 2 |
| Withdrew: Physician decision | 2 |
Percentage of participants with one or more adverse events (AEs)
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With Adverse Events (AEs) | 90.9 |
Percentage of participants who discontinued from study drug due to an AE
| Percentage of participants | Letermovir |
|---|---|
| Percentage of Participants Who Discontinued From Study Drug Due to an AE | 13.6 |
CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Participants who have undergone anti-CMV treatment was defined as initiation of approved anti-CMV agents based on at least one positive cell on CMV antigenemia and/or quantifiable CMV DNA PCR assay performed locally.
| Percentage of Participants | Letermovir | Letermovir D+/R- | Letermovir R+ |
|---|---|---|---|
| With CMV Disease or Started Anti-CMV Treatment Through Week 28 Post-Transplant | 0.0 (0.0 to 16.1) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 33.6) |
| With CMV Disease or Started Anti-CMV Treatment Through Week 52 Post-Transplant | 19.0 (5.4 to 41.9) | 33.3 (9.9 to 65.1) | 0.0 (0.0 to 33.6) |
CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included.
| Percentage of Participants | Letermovir | Letermovir D+/R- | Letermovir R+ |
|---|---|---|---|
| With CMV Disease Through Week 28 Post-Transplant | 0.0 (0.0 to 16.1) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 33.6) |
| With CMV Disease Through Week 52 Post-Transplant | 9.5 (1.2 to 30.4) | 16.7 (2.1 to 48.4) | 0.0 (0.0 to 33.6) |
Quantifiable CMV DNAemia (central) was defined as any case with a numeric value or \>910,000,000 (not including reporting of PCR results as "detected, not quantifiable") using the Roche COBAS® AmpliPrep/COBAS TaqMan® (CAP/CTM) assay, which was performed by the central laboratory.
| Percentage of participants | Letermovir | Letermovir D+/R- | Letermovir R+ |
|---|---|---|---|
| Quantifiable CMV DNAemia Through Week 28 Post-transplant | 4.8 (0.1 to 23.8) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 33.6) |
| Quantifiable CMV DNAemia Through Week 52 Post-transplant | 23.8 (8.2 to 47.2) | 41.7 (15.2 to 72.3) | 0.0 (0.0 to 33.6) |
AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an oral administration of letermovir.
| ng*hr/mL | Letermovir |
|---|---|
| Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment | 156000 ± 47.3 |
Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an oral administration of letermovir.
| ng/mL | Letermovir |
|---|---|
| Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment | 1700 ± 121.9 |
Cmax was defined as the maximum concentration of letermovir observed in plasma following an oral administration of letermovir.
| ng/mL | Letermovir |
|---|---|
| Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment | 17900 ± 31.1 |
Tmax was defined as the time required post dosing to reach a maximum plasma concentration of letermovir following an oral administration of letermovir.
| hr | Letermovir |
|---|---|
| Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment | 2.50 (0.92 to 23.35) |
Apparent clearance at steady state (CLss/F) of plasma letermovir following an oral administration of letermovir.
| L/hr | Letermovir |
|---|---|
| Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment | 3.08 ± 47.3 |
AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an IV administration of letermovir was intended to measure.
No measurements were reported for this outcome.
Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an IV administration of letermovir was intended to measure.
No measurements were reported for this outcome.
Ceoi is defined as the amount of letermovir in plasma following an IV administration of letermovir was intended to measure.
No measurements were reported for this outcome.
Clearance at steady state (CLss) of plasma letermovir following an IV administration of letermovir was intended to measure.
No measurements were reported for this outcome.
Collected over Up to week 52 post-transplant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letermovir | 0/22 (0%) | 7/22 (31.8%) | 13/22 (59.1%) |
| Event | Letermovir |
|---|---|
| ConstipationGastrointestinal disorders | 1/22 |
| Adenoviral haemorrhagic cystitisInfections and infestations | 1/22 |
| Herpes zosterInfections and infestations | 1/22 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 1/22 |
| TonsillitisInfections and infestations | 1/22 |
| Urinary tract infectionInfections and infestations | 1/22 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 1/22 |
| LymphoceleVascular disorders | 1/22 |
| Event | Letermovir |
|---|---|
| StomatitisGastrointestinal disorders | 4/22 |
| DiarrhoeaGastrointestinal disorders | 3/22 |
| Neutrophil count decreasedInvestigations | 3/22 |
| HyperlipidaemiaMetabolism and nutrition disorders | 3/22 |
| AnaemiaBlood and lymphatic system disorders | 2/22 |
| LeukopeniaBlood and lymphatic system disorders | 2/22 |
| NauseaGastrointestinal disorders | 2/22 |
| Urinary tract infectionInfections and infestations | 2/22 |
| Incisional herniaInjury, poisoning and procedural complications | 2/22 |
| InsomniaPsychiatric disorders | 2/22 |
| Age, Continuous(Years) | Letermovir |
|---|---|
| Mean | 48.5 ± 12.3 |
| Sex: Female, Male(Participants) | Letermovir |
|---|---|
| Female | 6 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | Letermovir |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Letermovir |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 22 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2019 to primary completion in Oct 2022, 33 months.
Results were first posted in Apr 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir